- Home
- FREY vs ACIU Comparison
FREY vs ACIU Comparison
Compare FREY & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FREY
- ACIU
- Stock Information
- Founded
- FREY 2018
- ACIU 2003
- Country
- FREY Luxembourg
- ACIU Switzerland
- Employees
- FREY N/A
- ACIU N/A
- Industry
- FREY Industrial Machinery/Components
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- FREY Miscellaneous
- ACIU Health Care
- Exchange
- FREY Nasdaq
- ACIU Nasdaq
- Market Cap
- FREY 293.4M
- ACIU 332.4M
- IPO Year
- FREY N/A
- ACIU 2016
- Fundamental
- Price
- FREY $2.18
- ACIU $2.68
- Analyst Decision
- FREY
- ACIU Strong Buy
- Analyst Count
- FREY 0
- ACIU 2
- Target Price
- FREY N/A
- ACIU $12.00
- AVG Volume (30 Days)
- FREY 2.7M
- ACIU 134.5K
- Earning Date
- FREY 11-06-2024
- ACIU 11-05-2024
- Dividend Yield
- FREY N/A
- ACIU N/A
- EPS Growth
- FREY N/A
- ACIU N/A
- EPS
- FREY N/A
- ACIU N/A
- Revenue
- FREY N/A
- ACIU $48,505,404.00
- Revenue This Year
- FREY N/A
- ACIU $85.33
- Revenue Next Year
- FREY $414.23
- ACIU $80.69
- P/E Ratio
- FREY N/A
- ACIU N/A
- Revenue Growth
- FREY N/A
- ACIU 4097200.00
- 52 Week Low
- FREY $0.91
- ACIU $2.25
- 52 Week High
- FREY $2.85
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- FREY 62.58
- ACIU 27.49
- Support Level
- FREY $1.56
- ACIU $2.62
- Resistance Level
- FREY $2.17
- ACIU $3.02
- Average True Range (ATR)
- FREY 0.19
- ACIU 0.13
- MACD
- FREY -0.00
- ACIU -0.05
- Stochastic Oscillator
- FREY 89.51
- ACIU 9.52
About FREY FREYR Battery Inc.
FREYR Battery Inc is an emerging producer of clean battery solutions for the planet. It designs and manufactures high-density and cost-competitive lithium-ion batteries with a reduced carbon footprint for the markets for electric mobility, stationary energy storage, and marine and aviation applications.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.